Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856394 | 1.00 | SLC29A1 (0.80) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL1979455 | 1.00 | SLC29A1 (0.80) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL8971093 | 0.91 | SLC29A1 (0.67) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL8971105 | 0.91 | SLC29A1 (0.67) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL6905077 | 0.91 | SLC29A1 (0.83) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL9346470 | 0.91 | SLC29A1 (0.83) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL9350420 | 0.91 | SLC29A1 (0.83) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL2581031 | 0.90 | SLC29A1 (0.69) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL27578774 | 0.85 | CYP2C19 (0.72) | SLC29A1CYP2C19ADORA3ADORA1PGK1 | |
| SCHEMBL13995542 | 0.85 | CYP2C19 (0.76) | SLC29A1CYP2C19ADORA3ADORA1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2509990-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-17 | — | — | EP | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2006-07-27 | — | — | US | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885CYP2C19 1329/4885ADORA3 95/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885CYP2C19 1329/4885ADORA3 95/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885CYP2C19 3438/4885ADORA3 729/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885CYP2C19 3438/4885ADORA3 729/4885 |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | NUDT1, NT5C2, DUT | SLC29A1 118/4885CYP2C19 4370/4885ADORA3 79/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885CYP2C19 3438/4885ADORA3 729/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885CYP2C19 3438/4885ADORA3 729/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885CYP2C19 1329/4885ADORA3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.